Around the Case

Short teaching entries for residents and fellows, centered on questions that come up in clinic — each linked to the best available evidence at the time of discussion. Focus: hemostasis, thrombosis & coagulation.

Use the search box at the top to find anything, browse the weekly summaries, or browse by tag.

All entries

• 0005 — How can someone who has a low factor VIII level of around 40% be considered to possibly have type 2N VWD?
• 0004 — What is the F8 gene duplication (FVIII Padua)?
• 0003 — Can we use Altuviiio (efanesoctocog alfa) for patients who have a history of inhibitors and underwent ITI?
• 0002 — Explain why there is discordance in FVIII activity after AAV gene therapy between one-stage (OS) and chromogenic substrate (CS) assays.
• 0001 — Why is there a discrepancy between clot-based one-stage assays and chromogenic assays in patients who have undergone gene therapy for hemophilia B?